Testing ACR246 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have an advanced solid tumor that has spread or come back, and standard treatments have stopped working or are not available.
- You must have a tumor that expresses a protein called 5T4 (this will be tested for the second part of the study).
- You must be in good enough health to be up and about (ECOG performance status 0 or 1).
- You must have adequate liver, kidney, and blood cell counts (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
This trial tests a new drug, GenSci143, for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has spread or come back and you have no other standard options left.
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new combination of two drugs (HRS2398 and Adebrelimab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.